3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
8
Melanoma
7
Colonic Neoplasms
4
Rectal Neoplasms
3
Skin Neoplasms
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Neoplasms
1
Solid Tumors
1
Pancreatic Neoplasms
1
Neoplasms
1
Lymphatic Metastasis
1
Leukemia, Hairy Cell
1
Gastrointestinal Neoplasms
1
Disease Progression
1
Digestive System Neoplasms
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Bevacizumab
3
palbociclib
2
ribociclib
1
repotrectinib
1
olaparib
1
encorafenib
1
durvalumab
1
atezolizumab
1
Tretinoin
1
Paclitaxel
1
Oviposition
1
Injections
1
Immunotherapy
1
Imatinib Mesylate
1
Fulvestrant
1
Drug Therapy
1
Drainage
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Digestive System Neoplasms
×
encorafenib
×
90 days
×
Clear all
NCT05039177
2026-03-25
HERKULES-3
Erasca, Inc.
Phase 1/2
Completed
101 enrolled